Incidence and prevalence of abnormal liver associated enzymes in patients with atrial fibrillation in a routine clinical care population

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 1, 2008, Pages 43-51

  Makar, George A ^a   Weiner, Mark G ^a   Kimmel, Stephen E ^a   Bennett, Dimitri ^b   Burke, Anne ^a   Yang, Yu Xiao ^a   Han, Xiaoyan ^a   Sellers, Kimberly ^c   Nessel, Lisa ^a   Lewis, James D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

Alanine aminotransferase; Atrial fibrillation; Drug induced Hepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; AMIODARONE; ANTICONVULSIVE AGENT; CLOPIDOGREL; COLESTYRAMINE; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIVER ENZYME; NICOTINIC ACID; ORAL ANTIDIABETIC AGENT; WARFARIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERLIPIDEMIA; INCIDENCE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTPATIENT; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT;

AGED; ALANINE TRANSAMINASE; ATRIAL FIBRILLATION; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HUMANS; INCIDENCE; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PREVALENCE; PRIMARY HEALTH CARE; REFERENCE VALUES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 38649127914     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1514     Document Type: Article

References (30)

1. Chugh SS, Blackshear JL, Shen WK, et al. Epidemiology and natural history of atria] fibrillation: clinical implications. J Am Coll Cardiol 2001; 37: 371-378. DOI: 10.1016/S0735-1097(00)01107-4
2. Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995; 155: 469-473.
3. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285:2370-2375.
4. Abusaada K, Sharma SB, Jaladi R, et al. Epidemiology and management of new-onset atrial fibrillation. Am J Manag Care 2004; 10: S50-S57.
5. Limdi JK, Hyde GM. Evaluation of abnormal liver function tests. Postgrad Med J 2003; 79: 307-312.
6. Kundrotas LW, Clement DJ. Serum alanine aminotransferase (ALT) elevation in asymptomatic US Air Force basic trainee blood donors. Dig Dis Sci 1993; 38: 2145-2150.
7. Strauss RS, Barlow SE, Dietz WH. Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. J Pediatr 2000; 136: 711-713.
8. Olsson SB, Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362: 1691-1698. DOI: 10.1016/S0140-6736(03)14841-6
9. Albers GW, Diener HC, Frison L, et al. SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005; 293: 690-698.
10. Is that it, then, for blockbuster drugs? Lancet 2004; 364: 1100. DOI: 10.1016/S0140-6736(04)17113-4
11. Boudes PF. The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee. Contemp Clin Trials 2006; 27:432-4340. DOI: 10.1016/ j.cct.2006.04.005
12. Kim HC, Nam CM, Jee SH, et al. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. Br Med J 2004; 328: 983. DOI:10.1136/ bmj.38050.593634.63
13. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-110.
14. Ruhl CE, Everhart JE. Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2005; 128: 24-32. DOI:10.1053/ j.gastro.2005.08.056
15. Reuben A. Hy's law. Hepatology 2004; 39: 574-578. DOI:10.1002/hep.20081
16. Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol 2006; 97S: 77-81C. DOI:10.1016/ j.amjcard.2005.12.014
17. Lewis JH, Ranard RC, Caruso A, et al. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology 1989; 9: 679-685.
18. Dunn GD, Hayes R Breen KJ, et al. The liver in congestive heart failure: a review. Am J Med Sci 1973; 265: 174-189.
19. Farrell GC, Latter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99-S112. DOI:10.1002/ hep.20973
20. Grundy SM, Cleeman JL, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005 2005; 112: 2735-2752. DOI:10.1161/CIRCULATIONAHA.105.169404
21. Temple RJ. Hepatotoxicity through the Years: Impact on the FDA [cited 2006 September 6]; available from http://www.fda.gov/cder/ livertox/Presentations/im1389/s1d002.htm
22. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003; 349:474-485.
23. Senior JR. How can 'Hy's law' help the clinician? Pharmacoepidemiol Drug Saf 2006; 15: 235-239. DOI: 10.1002/pds.1210
24. Temple RJ. Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 2006; 15: 241-243. DOI: 10.1002/ pds.1211
25. U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Drug-induced liver injury: a national and global problem. [cited 2006 August 7]; available from http://www.fda.gov/cder/livertox/ monday.htm
26. Lewis JH. 'Hy's law,' the 'Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective. Pharmacoepidemiol Drug Saf 2006; 15: 221-229. DOI: 10.1002/ pds.1209
27. Lee WM, Larrey D, Olsson R, et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf 2005; 28: 351-370.
28. Goldschlager N, Epstein AE, Naccarelli G, et al. Practical guidelines for patients who treat patients with amiodarone. Arch Intern Med 2000; 160: 1741-1748.
29. Chang CY, Schiano TD. Review article: drug hepatotoxicity. Aliment Pharamacol Ther 2007; 25: 1135-1151.
30. Kim HC, Nam CM, Jee SH, et al. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. Br Med J 2004; 328: 983-988.